|
Entwicklung von ALL* wird beendet
(*acute lymphoblastic leukemia), dafür will sich das Unternehmen nun voll auf den Produktkandidaten Eryaspase konzentrieren.
investors.erytech.com/...amp;p=irol-newsArticle&ID=2355698
Zu 9 € evtl einen Blick wert.
Erytech meldet Zahlen für H1/19
investors.erytech.com/news-releases/...rts-financial-results-6
Eryaspase bekommt "Fast-Track" Status von der FDA
investors.erytech.com/news-releases/...nation-eryaspase-second
"The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021"
investors.erytech.com/news-releases/...l-2l-pancreatic-cancer
"ERYTECH has requested a pre-BLA meeting and subject to the feedback received in that meeting, the Company plans to submit a Biologics License Application (BLA) in the second half of 2021 for its lead product candidate eryaspase for the treatment of hypersensitive ALL patients."
investors.erytech.com/news-releases/...cuss-path-approval-all
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
39 | Bioheroaktie mit upcoming keymilestones im Q4/17 | Evidencebased | Vassago | 16.02.23 19:25 |